| 摘要 |
The invention relates to a pharmaceutical formulation comprising a LTB4 antagonist having a hydroxy and a benzamidine group or a tautomer, a pharmaceutically acceptable salt or solvate thereof, in particular a compound of formula (I), wherein R and A are as defined in the claims, or a tautomer, a pharmaceutically acceptable salt or solvate thereof (1) and at least one cyclooxygenase-2 inhibitor, a combined cox1/2 inhibitor or a pharmaceutically acceptable salt or solvate thereof (2), and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.
|
